New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective.

Published on Mar 25, 2020in Metabolism-clinical and Experimental6.159
· DOI :10.1016/J.METABOL.2020.154218
Niki Katsiki45
Estimated H-index: 45
(A.U.Th.: Aristotle University of Thessaloniki),
Ele Ferrannini110
Estimated H-index: 110
,
Christos S. Mantzoros139
Estimated H-index: 139
(BIDMC: Beth Israel Deaconess Medical Center)
Sources
Abstract
📖 Papers frequently viewed together
2012
2 Citations
2014
1 Author (Naveed Sattar)
202016.02Diabetes Care
84 Citations
References50
Newest
#1Amalia GastaldelliH-Index: 85
#2Enrico Repetto (AstraZeneca)H-Index: 3
Last. Ele FerranniniH-Index: 110
view all 7 authors...
AIM: To assess the efficacy of exenatide (EXE) once weekly + dapagliflozin once daily (DAPA) versus each drug alone in reducing biomarkers of fatty liver/steatosis and fibrosis in a post hoc analysis of DURATION-8, a 104-week study in 695 patients with type 2 diabetes uncontrolled by metformin monotherapy. MATERIALS AND METHODS: We evaluated the impact of the study treatments on non-invasive markers of hepatic steatosis (fatty liver index [FLI] and non-alcoholic fatty liver disease [NAFLD] liver...
19 CitationsSource
#1Vasilios G. Athyros (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 69
#2Stergios A. Polyzos (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 47
Last. Christos S. Mantzoros (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 139
view all 7 authors...
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD), affecting over 25% of the general population worldwide, is characterized by a spectrum of clinical and histological manifestations ranging from simple steatosis (>5% hepatic fat accumulation without inflammation) to non-alcoholic steatohepatitis (NASH) which is characterized by inflammation, and finally fibrosis, often leading to liver cirrhosis, and hepatocellular carcinoma. Up to 70% of patients with type 2 diabetes mellitus (T2DM) have NA...
24 CitationsSource
#1Anthony P. Coll (Medical Research Council)H-Index: 34
#2Michael ChenH-Index: 4
Last. Stephen O'Rahilly (Medical Research Council)H-Index: 145
view all 33 authors...
Metformin, the world’s most prescribed anti-diabetic drug, is also effective in preventing type 2 diabetes in people at high risk1,2. Over 60% of this effect is attributable to the ability of metformin to lower body weight in a sustained manner3. The molecular mechanisms by which metformin lowers body weight are unknown. In two, independent randomised controlled clinical trials, circulating levels of GDF15, recently described to reduce food intake and lower body weight through a brain stem-restr...
113 CitationsSource
#1Chintan V. Dave (RU: Rutgers University)H-Index: 12
#2Sebastian Schneeweiss (Brigham and Women's Hospital)H-Index: 114
Last. Elisabetta Patorno (Brigham and Women's Hospital)H-Index: 29
view all 5 authors...
OBJECTIVE There is a paucity of data evaluating recent changes in clinical and prescriber characteristics of patients initiating sodium–glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA). RESEARCH DESIGN AND METHODS U.S.-based administrative-claims data (July 2013 to June 2018) were used to identify initiators of SGLT2i and GLP-1RA. RESULTS Over 5 years, empagliflozin initiation (as a proportion of SGLT2i) increased by 57.1% (P CONCLUSIONS For SGL...
16 CitationsSource
#1David M. Williams (Cardiff University)H-Index: 13
#1David M. Williams (Cardiff University)H-Index: 4
Last. Marc Evans (Cardiff University)H-Index: 28
view all 3 authors...
The development of chronic kidney disease (CKD) in people with diabetes is commonplace, and is frequently associated with a significant and unfavourable impact on patient outcomes along with a substantial economic burden. With the development of novel classes of drug therapies in diabetes, there has been a recent focus on cardiovascular safety measures, with dedicated cardiovascular outcome trials (CVOTs) carried out for all new diabetes medications. More recently, there has been a growing regul...
26 CitationsSource
#1Melanie J. Davies (University of Leicester)H-Index: 95
#2David A. D'Alessio (Duke University)H-Index: 85
Last. John B. Buse (UNC: University of North Carolina at Chapel Hill)H-Index: 118
view all 10 authors...
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication ...
713 CitationsSource
#1Amy S. Shah (UC: University of Cincinnati)H-Index: 3
#1Amy S. Shah (UC: University of Cincinnati)H-Index: 22
Last. Kristen J. Nadeau (DU: University of Denver)H-Index: 34
view all 2 authors...
The purpose of this review is to provide an update on the changing face of paediatric type 1 diabetes and type 2 diabetes. Paediatric diabetes is on the rise, with extensive research dedicated to understanding its pathophysiology, comorbidities and complications. As obesity continues to increase among all youth, differentiating between type 1 diabetes and type 2 diabetes has become increasingly difficult but remains important for optimising treatment, anticipating complications and predicting di...
3 CitationsSource
#1Hartmut Glossmann (Innsbruck Medical University)H-Index: 78
#1Hartmut Glossmann (Innsbruck Medical University)H-Index: 5
Last. Oliver M. D. LutzH-Index: 4
view all 2 authors...
Abstract Despite being a successful diabetes type 2 drug for more than a half-century in Europe, the mode of action of metformin is still debated. It is the purpose of this review to inform the reader about most recent findings for metformin with respect to its antidiabetic activity as well as proposed benefits beyond glucose control in humans. Clinical evidence now suggests that most of metformin benefits originate from its actions in the gut, involving hormone signaling by glucagon-like peptid...
15 CitationsSource
#1Niki Katsiki (AHEPA University Hospital)H-Index: 10
#1Niki Katsiki (AHEPA University Hospital)H-Index: 45
Last. Dimitri P. Mikhailidis (UCL: University College London)H-Index: 109
view all 3 authors...
8 CitationsSource
#1Nikolaos Perakakis (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 17
#2Stergios A. Polyzos (A.U.Th.: Aristotle University of Thessaloniki)H-Index: 47
Last. Christos S. Mantzoros (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 139
view all 7 authors...
Abstract Background Non-alcoholic fatty liver disease (NAFLD) affects 25–30% of the general population and is characterized by the presence of non-alcoholic fatty liver (NAFL) that can progress to non-alcoholic steatohepatitis (NASH), liver fibrosis and cirrhosis leading to hepatocellular carcinoma. To date, liver biopsy is the gold standard for the diagnosis of NASH and for staging liver fibrosis. This study aimed to train models for the non-invasive diagnosis of NASH and liver fibrosis based o...
39 CitationsSource
Cited By4
Newest
#1Ferdinando Carlo Sasso (Seconda Università degli Studi di Napoli)H-Index: 34
#2Pia Clara Pafundi (Seconda Università degli Studi di Napoli)H-Index: 12
Last. Luca Rinaldi (Seconda Università degli Studi di Napoli)H-Index: 18
view all 20 authors...
Abstract Background and Aims Beyond type 2 diabetes, even a condition of prediabetes is associated with an increased cardiovascular (CV) risk, and HCV infection coexistence represents an exacerbating factor. CV prognosis improvement in prediabetes represents a challenge, due to the increasing prevalence of this metabolic condition worldwide. Hence, we aimed to prospectively assess how direct acting antivirals (DAAs) could affect major cardiovascular events (MACE) in a prediabetic HCV positive co...
1 CitationsSource
#1Walter Masson (Hospital Italiano de Buenos Aires)H-Index: 8
#2Augusto Lavalle-Cobo (Hospital Italiano de Buenos Aires)H-Index: 3
Last. Graciela MolineroH-Index: 7
view all 5 authors...
Aims To evaluate the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs) on major cardiovascular events (MACE) in metformin-naive patients with type 2 diabetes (T2D). Methods and results A meta-analysis was performed of randomized controlled clinical trials of GLP-1RAs and SGLT-2 inhibitors on T2D populations, after searching the PubMed/MEDLINE, Embase, and Cochrane Controlled Trials databases. The primary endpoint was MACE. The s...
5 CitationsSource
#1Muhammad Qamar Masood (Aga Khan University)H-Index: 6
#1Muhammad Qamar Masood (Aga Khan University)H-Index: 3
Last. Nikhil Tandon (AIIMS: All India Institute of Medical Sciences)H-Index: 68
view all 17 authors...
Abstract Objective To assess the predictors of achieving and maintaining guideline-recommended glycemic control in people with poorly controlled type 2 diabetes. Methods We analyzed data from the Centre for Cardiometabolic Risk Reduction in South Asia (CARRS) Trial (n=1146), to identify groups that achieved guideline-recommended glycemic control (HbA1c 9%) over a median of 28 months of follow-up. We used generalized estimation equations (GEE) analysis for each outcome i.e. achieving guideline-re...
1 CitationsSource
#1Niki Katsiki (AHEPA University Hospital)H-Index: 10
#1Niki Katsiki (AHEPA University Hospital)H-Index: 45
Last. Dimitrios Tousoulis (UoA: National and Kapodistrian University of Athens)H-Index: 39
view all 2 authors...
4 CitationsSource